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and students (18.3%). The majority (83.2%) were treated with podophyllin paints. 
At 6 months, 55.0% were cured, 25.2% still had ongoing genital warts, 5.7% had a 
recurrence, 12.2% were lost to follow-up and 1.5% was discontinued. The median 
direct medical costs were 998 (range 130–4060) Thai Baht. All patients were treated 
as out-patient cases and 71.7% came to hospital without work absenteeism. After 
having genital warts lesion, work productivity was reduced to 83.0% (17.3) and daily 
activity was also declined to 82.4% (14.4) from baseline. CONCLUSIONS: Anogeni-
tal warts are common STI and tend to be recalcitrant to treatment. They also lead to 
the reduction on work productivity and daily activity. 
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OBJECTIVES: In Korea, rotavirus gastroenteritis rarely causes mortality, but it causes 
signiﬁ cant morbidity among young children. The objective of this study was to estimate 
the public health burden and the potential impact of universal vaccination with a three-
dose pentavalent rotavirus vaccine in Korea. METHODS: A Markov cohort simulation 
model was developed to project the expected clinical burden of rotavirus gastroenteritis 
and the potential impact of universal vaccination (vs.no vaccination) if all children are 
given a three-dose pentavalent rotavirus vaccine for the 2007 birth cohort of 493,189 
Korean infants during the ﬁ rst 5 years of life. Vaccine efﬁ cacy for preventing rotavirus 
and the associated use of health-care resources was based on the Rotavirus Efﬁ cacy and 
Safety Trial (REST) results. Data on rotavirus related health-care resource utilization 
were based on published sources. Data on the cost of treating rotavirus diarrhea were 
extracted from a hospital cost survey and the National Health Insurance claims data. 
One-way sensitivity analysis was conducted by varying the health-care resource utiliza-
tion and the discount rate from 3% to 7%. RESULTS: The three-dose rotavirus vaccina-
tion program would result in the prevention of 181,238 symptomatic cases (reduction 
rate: 63.2%), 27,200 hospital admissions (90.8%), 7602 emergency department visits 
(86.5%), and 538,399 outpatient visits (76.7%) during the 5 years after birth if all 
children are vaccinated. The break even price of vaccination was estimated to be between 
KW 50,454 and 61,667 per dose. CONCLUSIONS: Implementing a three-dose univer-
sal rotavirus vaccination strategy would likely result in a substantial reduction in 
rotavirus related health-care resource utilization in Korea. These results may be useful 
for evaluating rotavirus vaccination programs in Korea. 
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OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 
1-year peginterferon alfa-2a compared to 3 years entecavir for the treatment of 
HBeAg-positive chronic hepatitis B in China. METHODS: A Markov health-state 
model was designed to evaluate the direct medical costs and outcomes (life-years and 
QALYs gained) of treating HBeAg-positive chronic hepatitis B in China. The model 
included 10 health states—Chronic hepatitis B (CHB), HBeAg seroconversion, HBsAg 
loss, CHB with resistance, Compensated cirrhosis, Decompensated cirrhosis, Hepato-
cellular carcinoma, Liver transplant, Post-liver transplant and death. The model incor-
porates a maximum analysis time horizon of 80 years with yearly cycles. The clinical 
and quality of life data were obtained from published literature and re-conﬁ rmed 
based on a questionnaire survey from a clinical expert panel of 20 hepatitis B special-
ists. From the perspective of China’s health insurance system, cost data was calculated 
based on the published literature about economic burden of chronic hepatitis B. A 
discounting rate at 3% was used to discount medical costs happened at different years. 
A univariate sensitivity analysis was performed to understand the key drivers and 
general sensitivity of the model. RESULTS: The model results showed that the utiliza-
tion of 1-year peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 
0.885 QALYs, compared to the 3 years entecavir treatment. The total cost per patient 
treated with peginterferon alfa-2a was CNY 151,770 (US$ 22,221), and CNY 
129,239 (US$ 18,922) for patient treated with entecavir. The discounted incremental 
cost per QALY gained for pegainterferon alfa-2a was CNY 25,452 (US$ 3,727). 
CONCLUSIONS: The results of the model suggest that 1 year pegainterferon alfa-2a 
improves health outcomes in a cost-effective manner compared with 3 years entecavir 
in the treatment of HBeAg-positive chronic hepatitis B in China. 
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OBJECTIVES: Several decision support tools have been developed to aid policy 
decision-making regarding the adoption of pneumococcal conjugate vaccine (PCV) 
into national immunization programs. Lacking critical evaluation of the tools causes 
decision-makers difﬁ culties in understanding and feeling ownership of information 
resulting from the tools, particularly in resource poor countries where technical capac-
ity is lacking. This study aims to critically compare decision-making tools and their 
cost-effectiveness (CE) ﬁ ndings, and to identify inﬂ uential parameters in the models. 
The overall objective is to provide decision makers with a menu of CE tools and their 
characteristics for their optimal use rather than to recommend a single model. 
METHODS: The WHO requested access to publicly available CE tools for PCV from 
both public and private provenance. All tools were assessed according to WHO’s 
economic evaluation guideline. All key attributes and characteristics were compared. 
A series of sensitivity analyses were performed to determine the major drivers of the 
models. The results were compared using a standardized set of input parameters. 
RESULTS: Three CE tools, including PAHO ProVac’s TriVac, PneumoADIP and 
GSK’s SUPREMES tools, were provided. They all compared the adoption of PCV into 
national immunization program with no immunization. The models differed in terms 
of attributes, structure, and data requirement, but captured similar range of diseases. 
Herd effect was estimated using different approaches. The main driving parameters 
were vaccine efﬁ cacy against pneumococcal pneumonia, vaccine price and coverage, 
serotype coverage and disease burden. With a standardized set of input parameters, 
TriVac and PneumoADIP provided similar ﬁ ndings including incremental costs, 
outcome and incremental cost-effectiveness ratio. CONCLUSIONS: Models differed 
in terms of model structure and key assumptions. Vaccine price and efﬁ cacy were the 
most inﬂ uential parameters. Understanding differences and similarities of CE tools 
could provide policymakers more efﬁ cient use for aiding their decision-making 
process. 
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OBJECTIVES: Cost-effectiveness studies using local health data have supported the 
long-term health and economic beneﬁ ts of the 7-valent pneumococcal conjugate 
vaccine (PCV-7) due to herd immunity, which also led to its inclusion in the routine 
immunization program for infants in Hong Kong in September 2009. The aim of the 
present study is to assess the clinical and economic impacts of the new PCV-13 vaccine 
on the whole population of Hong Kong compared to no vaccination. METHODS: A 
decision analytical model modiﬁ ed from the recent Prevenar 13Ò Economic Impact 
(PREVENT) Model (RTI Health SolutionÒ) was used for the analysis of the outcomes 
of vaccination. The whole population of Hong Kong of around 7 million was analyzed 
with infants ≤2 either vaccinated or not vaccinated with PCV-13. Population data, 
incidence rates, serotype coverage, disease sequelae, mortality rates, vaccine effective-
ness, duration of protection, herd effects, utilities, cost of vaccination, and other direct 
costs were adopted from local published studies, previous economic assessments of 
PCV-7/PCV-13 and local government sources to populate the model. Data were 
adopted from overseas published studies if local data was not available. Sensitivity 
analyses were performed to check the robustness of the results. The time horizon was 
one year and the study was performed from a public health-care organization perspec-
tive. RESULTS: Over 1 year, our analysis shows for a four-dose regimen of PCV-13: 
a gain of 17 quality-adjusted-life-years (QALY), an avoidance of 1281 related illnesses 
and two deaths. Cost/life-year gained was US-145,014 and cost/QALY was 
-US161,127. CONCLUSIONS: Based on the WHO recommended international 
thresholds for cost-effectiveness, with GDP per capita of Hong Kong being US29,902 
in 2009, our study results suggest PCV-13 vaccination is very cost-effective in provid-
ing protection to the people of Hong Kong from the perspective of a public health-care 
organization. 
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OBJECTIVES: To perform a cost-effectiveness analysis of universal newborn vaccina-
tion against hepatitis B virus (HBV) and to identify the affordability of the program 
in Viet Nam, a highly endemic country of HBV infection. METHODS: Marginal cost 
of every life-year and quality-adjusted life-year (QALY) gained with universal newborn 
vaccination against HBV was calculated using a Markov model. Two types of analyses 
(including and excluding expenditure on the treatment of chronic hepatitis B and its 
complications) were performed. We conducted one-way sensitivity analyses to conﬁ rm 
the robustness of the results. We used Monte Carlo simulations to examine the afford-
ability of the vaccination program from payer’s perspective to derive an affordability 
curve for the program. RESULTS: In the base-case scenario, universal newborn vac-
cination against HBV reduced the carrier rate by 72%, and increase number of life-
years and QALY gained of a 2008 birth cohort by 1.8 years (71.21 years vs. 69.41 
years) and 2.26 years (71.03 years vs. 68.77 years), respectively. Marginal cost per 
life-year and per QALY gained were US$ 18.82 and US$ 13.16, much lower than the 
annual GDP per capita of around US$1024). The probability of the vaccination 
program to be both cost-effective and affordable is 60% at an annual program cost 
of US$253,000 (from the payer’s perspective), where the threshold cost-effective value 
is US$ 13.16 per QALY gained. CONCLUSIONS: Universal newborn vaccination 
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against HBV is highly cost-effective in Viet Nam. As a low-income, endemic country 
where funds are limited and economic results of vaccination are uncertain, afford-
ability options allow decision-makers to make proper health investment in vaccination 
strategies against HBV. In the long run, adolescents should also be universally vac-
cinated against HBV. 
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OBJECTIVES: To assess the cost-effectiveness of mobile phone “contact-reminder” 
compared to self-administered treatment (SAT) to control tuberculosis (TB) in Thai-
land. METHODS: Cost-effectiveness analysis was undertaken using a decision tree 
model, which included three stages of treatment; initial treatment, re-treatment, and 
multi-drug resistant TB treatment. Costs (2005 international dollars: I$) were calcu-
lated based on treatment periods and treatment outcomes. Health outcomes were 
estimated over the lifetime of smear-positive pulmonary TB patients in disability-
adjusted life-years (DALYs). Both costs and health outcomes were discounted 3% 
annually. Mobile phone reminders are a relatively new TB treatment strategy. A pilot 
study reported a mortality rate far higher than observed using other strategies, but 
there were reasons to suspect this was inﬂ uenced by the high age and comorbidities 
of the trial sample. We undertook a sensitivity analysis using mortality rates observed 
during other treatment strategies, to indicate if mobile phone reminders could be 
cost-effective in Thailand. RESULTS: Sensitivity analysis showed lowering the mortal-
ity rate to values observed in trials of other treatment strategies made the mobile phone 
reminder intervention more cost-effective than SAT, as a result of an increase in the 
DALYs averted. Using the highest (8%) and the lowest (3%) death rates from the 
other TB control strategies, the probability that the mobile phone intervention was 
more cost-effective than SAT was 98% and 100%, respectively. CONCLUSIONS: If 
further trials show the mortality rate using a mobile phone reminder system to be 
similar to that observed under other treatment strategies, this strategy would be more 
cost-effective than SAT. A bigger study with control group and proper age distribution 
is needed to examine the true merits of mobile phone intervention. 
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OBJECTIVES: To assess the comparative costs and outcomes of HIV treatment 
algorithms with and without the use of raltegravir for treatment naïve patients. 
METHODS: A cost-utility analysis was constructed using a Markov model to assess 
the incremental cost per QALY gained of a HIV treatment algorithm which included 
raltegravir as a ﬁ rst line treatment compared to standard practice in Australia. Com-
parator treatment algorithms were constructed for patients initiating treatment with 
a non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimen and 
patients initiating treatment with a protease-inhibitor (PI) containing regimen. The 
economic model was a Markov cohort model with the cohort transited through ﬁ ve 
health states which reﬂ ect four lines of the treatment in each algorithm and death. 
The modeled population cycled through the treatment algorithm upon loss of virologic 
response and at each cycle are at risk of adverse events, AIDS events and death based 
on the treatment regimen received, viral load and CD4 count. The efﬁ cacy and safety 
of each treatment at each line of the algorithm was based on randomized clinical trial 
data and a mixed treatment comparison. Costs were calculated from the perspective 
of the Australian health-care system. The economic model was a lifetime model. 
RESULTS: The raltegravir algorithm was more costly than the NNRTI algorithm 
(A$4487 per patient) but less costly than the PI algorithm (A$18,383 per patient). 
The raltegravir algorithm had greater QALYs than both the comparator algorithms 
(0.17 and 0.22 per patient compared to the NNRTI and PI algorithms respectively). 
The incremental cost per QALY of the raltegravir algorithm compared to the NNRTI 
regimen was A$26,896 which is considered within an acceptable threshold in Austra-
lia. The raltegravir algorithm dominated the PI algorithm (lower costs and greater 
QALYs). CONCLUSIONS: Raltegravir for treatment naïve patients is an effective and 
cost-effective intervention relative to current practice in Australia. 
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OBJECTIVES: To assess the cost-effectiveness of daptomycin versus glycopeptides 
(vancomycin and teicoplanin), the most widely used alternatives in the treatment of 
patients with infective endocarditis and bacteremia caused by Methicillin resistant 
Staphylococcus Aureus (MRSA) from the perspective of Turkish health-care system. 
METHODS: The clinical trials with daptomycin were powered to show non-inferior-
ity against vancomycin. The model is based on a cost-minimization analysis, assuming 
similar efﬁ cacy between daptomycin and glycopeptides. However, median length of 
inpatient treatment, hence hospital stay differed among therapies in the trial. A 
decision-analytic model was designed to estimate the use of resources and costs based 
on treatment duration and patterns. The model time horizon was from the ﬁ rst day 
of the hospitalization to successful treatment. Resource utilization was collected from 
literature and complemented with the help physician survey in Turkey. Resource use 
consisted of drug costs, iv and im administration costs, monitoring and hospitalization 
costs. Key parameters and assumptions in the model were explored in sensitivity 
analyses to determine their impact on the model outcome. RESULTS: The use of 
daptomycin as ﬁ rst-line therapy resulted in lower cost per patient despite signiﬁ cant 
daily drug cost difference between alternatives. Total health-care costs per patient were 
f2069 for the daptomycin whereas f2392 and f2419 for the vancomycin and teico-
planin arms respectively, resulting in f323-f350 savings per person with daptomycin 
treatment. The main cost driver was drug costs, which was responsible for 66% of 
the total costs on average. CONCLUSIONS: Daptomycin is less costly than both 
vancomycin and teicoplanin in the treatment of MRSA induced bacteremia and infec-
tive endocarditis when used as ﬁ rst-line therapy. The cost-savings with daptomycin in 
Turkey largely stem from shorter treatment duration with daptomycin due to its highly 
effective and rapid bactericidal activity. 
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OBJECTIVES: To assess the value for money of introducing three-drug antiretroviral 
regimens, namely 1) zidovudine—AZT, lamivudine—3TC, and efavirenz—EFV; or 2) 
AZT, 3TC, and lopinavir/ritonavir—LPV/r, in comparison to the current protocol, 
AZT plus single-dose nevirapine–sd-NVP, for the prevention of mother-to-child trans-
mission (PMTCT) of HIV in Thailand. METHODS: A decision tree was constructed 
to predict costs and outcomes using the Thai governmental perspective. The costs 
consisted of 1) program costs; 2) costs of treatment of premature birth; 3) costs of 
treatment of pediatric HIV infection; and 4) costs of treatment of drug resistance 
among mothers. All costs were presented in 2009 Thai baht. The outcome was mea-
sured in terms of quality-adjusted life-years (QALYs) gained from infant HIV infection 
averted. The costs and outcomes were discounted with the rate of 3% as recommended 
by the national guidelines. RESULTS: Introduction of the three-drug antiretroviral 
regimens yields lower costs and better health outcomes compared to AZT + sd-NVP. 
Although these three-drug regimens offer higher program costs and health-care costs 
for premature birth, they signiﬁ cantly save money in regard to pediatric HIV treatment 
and treatment costs for drug resistance in the mothers. In addition, approximately 1 
QALY is averted as a result of using the regimens. Because of the lack of clinical 
evidence to distinguish the difference in terms of PMTCT efﬁ cacy between EFV-based 
and LPV/r-based regimens, the analysis favors a cheaper EFV-based regimen. Results 
from univariate uncertainty analysis also support the above conclusion and a tornado 
diagram presents the relative importance of each model input parameter. CONCLU-
SIONS: The three-drug regimens are cost-saving for PMTCT in Thailand, and ﬁ ndings 
from this study support a change in the National PMTCT guidelines in the country. 
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OBJECTIVES: In Indonesia, legislation mandates a medical prescription for purchase 
of antibiotics. However, the use of nonprescribed antibiotics is widespread among the 
population. Therefore, the aim of this study was to elicit common beliefs about the 
use of antibiotics without prescription among Indonesians in an urban area of Yog-
yakarta. METHODS: Adults (>18 years old) with experience of using nonprescribed 
antibiotics, including leftovers from previously prescribed medication were inter-
viewed. The questions focused on the advantages, disadvantages, enabling factors and 
social pressure related to this behavior. Two researchers independently analyzed the 
qualitative data using thematic analysis. RESULTS: A total of 25 face to face inter-
views has been conducted. Saving money and saving time—as a result of avoiding a 
medical consultation—were two main advantages of using nonprescribed antibiotics. 
Moreover, this behavior was reported as preventing the participants from taking too 
many different types of medicines commonly prescribed by doctors. Despite insurance 
coverage for the cost of prescribed medicines and medical consultation fees, some 
participants preferred to purchase nonprescribed antibiotics out-of-pocket because of 
the perceived advantages mentioned. Availability of antibiotics to be purchased 
without prescription in pharmacies as well as their accessibility in shops, and previous 
